Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03647423
Recruitment Status : Not yet recruiting
First Posted : August 27, 2018
Last Update Posted : August 27, 2018
Sponsor:
Information provided by (Responsible Party):
NantKwest, Inc.

Brief Summary:
QUILT 3.091 Chordoma Vaccine: Phase 1B/2 NANT Chordoma Vaccine vs Radiation in Subjects with Unresectable Chordoma.

Condition or disease Intervention/treatment Phase
Chordoma Unresectable Malignant Neoplasm Biological: Aldoxorubicin Hydrochloride Biological: ALT-803 Biological: ETBX-051 Biological: ETBX-061 Biological: GI-6301 Biological: haNK Drug: Avelumab Drug: Cetuximab Drug: Cyclophosphamide Radiation: SBRT Phase 1 Phase 2

Detailed Description:

The NANT Chordoma Vaccine regimen will be administered in 2 phases, an induction and a maintenance phase.

Subjects will continue induction treatment for up to 1 year. Those who have a confirmed complete response (CR) in the induction phase will enter the maintenance phase of the study. Subjects who experience ongoing stable disease (SD) or an ongoing partial response (PR) at 1 year may enter the maintenance phase at the Investigator's and Sponsor's discretion. Subjects may remain in the maintenance phase of the study for up to 1 year.

In the randomized component of the phase 2 portion of the study, the control arm will be treated with radiation according to established SoC protocols as determined by the Investigator.

In the phase 2 single-arm component of the study, subjects will be enrolled in the first stage of Simon's two-stage optimal design. If the study proceeds to the second stage of Simon's two-stage optimal design, additional subjects will be enrolled in the second stage.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 427 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Chordoma Vaccine: A randomized phase 1b/2 trial of the NANT chordoma vaccine vs. radiation in subjects with unresectable chordoma.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: QUILT-3.091 NANT Chordoma Vaccine: A Randomized Phase 1b/2 Trial of the NANT Chordoma Vaccine vs. Radiation in Subjects With Unresectable Chordoma.
Estimated Study Start Date : August 31, 2018
Estimated Primary Completion Date : August 31, 2020
Estimated Study Completion Date : August 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: NANT Chordoma Vaccine
A combination of agents will be administered to subjects in this study: Aldoxorubicin Hydrochloride HCI, ALT-803, ETBX-051, ETBX-061, GI-6301, haNK, avelumab, cetuximab, cyclophosphamide, SBRT.
Biological: Aldoxorubicin Hydrochloride
Aldoxorubicin Hydrochloride HCI

Biological: ALT-803
Recombinant human super agonist interleukin-15 (IL-15) complex

Biological: ETBX-051
Ad5 [E1-, E2b-]-Brachyury

Biological: ETBX-061
Ad5 [E1-, E2b-]-mucin 1 [MUC1]

Biological: GI-6301
Brachyury yeast

Biological: haNK
haNK™, NK-92 [CD16.158V, ER IL-2]

Drug: Avelumab
injection
Other Name: BAVENCIO®

Drug: Cetuximab
Injection
Other Name: ERBITUX®

Drug: Cyclophosphamide
Capsules
Other Name: Cytoxan

Active Comparator: Controlled Arm - Radiation
SBRT
Radiation: SBRT
Stereotactic body radiation therapy




Primary Outcome Measures :
  1. Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03. [ Time Frame: 9 weeks ]
    Phase 1b primary endpoint

  2. Progression-free survival (PFS) by RECIST v1.1 [ Time Frame: 1 years ]
    Phase 2 primary endpoint


Secondary Outcome Measures :
  1. Objective response rate by RECIST v1.1 [ Time Frame: 9 weeks ]
    Phase 1b secondary endpoint

  2. Objective response rate by irRC [ Time Frame: 9 weeks ]
    Phase 1b secondary endpoint

  3. Progression-free survival (PFS) by RECIST v1.1 [ Time Frame: 9 weeks ]
    Phase 1b secondary endpoint

  4. Progression-free survival (PFS) by irRC [ Time Frame: 9 weeks ]
    Phase 1b secondary endpoint

  5. Overall survival [ Time Frame: 9 weeks ]
    Phase 1b secondary endpoint

  6. Disease control rate by RECIST v1.1 and irRC. [ Time Frame: 1 year ]
    Phase 1b secondary endpoint

  7. Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months) by RECIST v1.1 and irRC. [ Time Frame: 1 year ]
    Phase 1b secondary endpoint

  8. Patient-reported outcomes of Chordoma cancer symptoms [ Time Frame: 1 year ]
    Phase 1b secondary endpoint (by RECIST v1.1 and irRC and FACT-Hep questionnaire)

  9. Progression-free survival (PFS) by irRC [ Time Frame: 1 year ]
    Phase 2 secondary endpoint

  10. Objective response rate by RECIST 1.1 [ Time Frame: 1 year ]
    Phase 2 secondary endpoint

  11. Objective response rate by irRC [ Time Frame: 1 year ]
    Phase 2 secondary endpoint

  12. Overall survival [ Time Frame: 1 year ]
    Phase 2 secondary endpoint

  13. Duration of response by RECIST and irRC [ Time Frame: 1 year ]
    Phase 2 secondary endpoint

  14. Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months) by RECIST and irRC. [ Time Frame: 1 year ]
    Phase 2 secondary endpoint

  15. Patient-reported outcomes of Chordoma cancer [ Time Frame: 1 year ]
    Phase 2 secondary endpoint

  16. Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03. [ Time Frame: 1 year ]
    Phase 2 secondary endpoint by (RECIST v1.1 and irRC and FACT-Hep questionnaire)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or Independent Ethics Committee (IEC) guidelines.
  3. Histologically-confirmed recurrent or unresectable chordoma that would require radiation as a primary means for treatment.
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  5. Have at least 1 measurable lesion of ≥ 1.0 cm.
  6. Must have a recent formalin-fixed, paraffin-embedded (FFPE) tumor biopsy specimen following the conclusion of the most recent anticancer treatment and be willing to release the specimen for prospective and exploratory tumor molecular profiling. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period, if considered safe by the Investigator. If safety concerns preclude collection of a biopsy during the screening period, a tumor biopsy specimen collected prior to the conclusion of the most recent anticancer treatment may be used.
  7. Must be willing to provide blood samples prior to the start of treatment on this study for tumor molecular profiling and exploratory analyses.
  8. Must be willing to provide a tumor biopsy specimen 8 weeks after the start of treatment for exploratory analyses, if considered safe by the Investigator.
  9. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
  10. Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception for up to 1 year after completion of therapy, and non- sterile male subjects must agree to use a condom for up to 4 months after treatment. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), and abstinence.

Randomized component only - 11. Must be able to be classified into at least 1 of the below 3 categories: i. Recurred within 6 months after treatment, ii. Have metastatic disease, iii. Meet ≥ 4 of the histopathologic and immunohistochemical criteria: • Poorly differentiated histopathologic sub type, • Mitotic figures ≥ 3, • Apoptosis present. • Prominent nucleoli present, • Necrosis present, • Ki67 ≥ 6%, • p53 ≥ 25%

Single-arm component only 12. Must have progressed on or after radiation monotherapy in the randomized portion of the study OR been ineligible for the randomized portion but had progressed or experienced unacceptable toxicity on SoC prior to enrollment on the study.

Exclusion Criteria:

  1. Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications.
  2. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis,Addison's disease, or autoimmune disease associated with lymphoma).
  3. History of organ transplant requiring immunosuppression.
  4. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
  5. Inadequate organ function, evidenced by the following laboratory results: a. Absolute neutrophil count < 1,000 cells/mm^3, b. Uncorrectable grade 3 anemia (hemoglobin < 8 g/dL), c. Platelet count < 75,000 cells/mm^3, d. Total bilirubin greater than the upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome), e. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases), f. Alkaline phosphatase levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases), g. Serum creatinine > 2.0 mg/dL or 177 μmol/L, h. Serum anion gap > 16 mEq/L or arterial blood with pH < 7.3.
  6. Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication. Subjects with uncontrolled hypertension should be medically managed on a stable regimen to control hypertension prior to study entry.
  7. Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection fraction (LVEF) 10% below the institution's lower limit of predicted normal.
  8. Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy.
  9. Positive results of screening test for human immunodeficiency virus (HIV).
  10. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.
  11. Known hypersensitivity to any component of the study medication(s).
  12. Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications.
  13. Concurrent or prior use of a strong cytochrome P450 (CYP)3A4 inhibitor (including ketoconazole, itraconazole, posaconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, and grapefruit products) or strong CYP3A4 inducers (including phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, and St John's Wort) within 14 days before study day 1.
  14. Concurrent or prior use of a strong CYP2C8 inhibitor (gemfibrozil) or moderate CYP2C8 inducer (rifampin) within 14 days before study day 1.
  15. Participation in an investigational drug study or history of receiving any investigational treatment within 30 days prior to screening for this study, except for testosterone- lowering therapy in men with prostate cancer.
  16. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  17. Concurrent participation in any interventional clinical trial.
  18. Pregnant and nursing women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03647423


Contacts
Layout table for location contacts
Contact: NantKWest Clinical Review Team 800-988-6083 clinical.trials@NantKwest.com

Locations
Layout table for location information
United States, California
Chan Soon-Shiong Institute for Medicine
El Segundo, California, United States, 90245
Sponsors and Collaborators
NantKwest, Inc.

Layout table for additonal information
Responsible Party: NantKwest, Inc.
ClinicalTrials.gov Identifier: NCT03647423     History of Changes
Other Study ID Numbers: QUILT-3.091
First Posted: August 27, 2018    Key Record Dates
Last Update Posted: August 27, 2018
Last Verified: August 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Chordoma
Vaccines
Cyclophosphamide
Cetuximab
Doxorubicin
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antineoplastic Agents, Immunological
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors